23069-91-2

Usage

Uses

Used in Organic Synthesis:
5-[(phenylamino)methylidene]pyrimidine-2,4,6(1H,3H,5H)-trione is used as an intermediate in the synthesis of various organic compounds due to its unique structural features and reactivity.
Used in Medicinal Chemistry:
5-[(phenylamino)methylidene]pyrimidine-2,4,6(1H,3H,5H)-trione is used as a potential therapeutic agent for its potential biological activities, such as antifungal, antibacterial, or antiviral properties. Its application in this field is aimed at developing new drugs that can combat infections and diseases.
Further studies are required to fully understand the therapeutic potential of 5-[(phenylamino)methylidene]pyrimidine-2,4,6(1H,3H,5H)-trione and to explore its possible applications in different industries.

Upstream product

• 123-91-1 1,4-dioxane 
• 67-52-7 BARBITURIC ACID 
• 864131-95-3 N,N'-diphenylformamidine 
• 110-86-1 pyridine 
• 1197040-29-1 phenyl isocyanate 
• 103-70-8 Formanilid 
• 62-53-3 aniline 
• 4425-60-9 5-formyl-2,4,6-pyrimidinetrione 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 4425-60-9 5-formyl-2,4,6-pyrimidinetrione 

Relevant academic research and scientific papers

Copper(II) complexes with barbiturate derivatives: Synthesis, characterization and catalytic applications

Barbiturate derivatives were prepared by the reaction of 5-formylbarbiturates and primary aryl amines. The corresponding copper(II) complexes were synthesized by treatment of copper(II) acetate monohydrate with the prepared barbiturate derivatives. All th

Computer-aided design, synthesis, and biological evaluation of 5-substituted aminomethylenepyrimidine-2,4,6-triones as H1 antihistaminic agents(Part2)

As a part of a research project pertaining to the synthesis of novel candidates as nonsedating, nonclassic H1 histaminergic (H1) blockers with low toxicity profiles, some new 5-substituted aminomethylenepyrimidine-2,4,6-triones were designed based on the H1 histaminic receptor pharmacophore model. The interactions between the designed compounds and the H1 receptor were studied using molecular docking on the homology model of H1 receptor. The designed compounds were synthesized and biologically evaluated for H1-blocking activity; using isolated segments of guinea pig ileum. Compounds 15,18,19 and 21 exhibited comparable activities to acrivastine (22) as reference nonsedating drug. The C log P of designed compounds revealed lower values in reference to acrivastine (22) which might indicate decreased tendency for crossing the blood brain barrier.